Sensors glean information from radiofrequency ID chips embedded in labels of contrast bottles
VistaTrak looks like a basic cabinet designed to hold bottles of contrast media. Wall-hung and compact, it seems a practical way to keep these bottles handy for use. But mounted to the side of this cabinet is a touchscreen that hints that VistaTrak may be more than it appears.
Lying in wait beneath its simple exterior are sensors that pick up signals from radiofrequency identification (RFID) chips attached to bottles of contrast. These signals indicate the lot number, expiration date, and other information when each bottle is removed from the cabinet. VistaTrak transmits these data to an inventory management system so managers can track the use of contrast and determine when stocks need to be replenished. It even checks automatically for compliance with dosing protocols.
“VistaTrak allows hospitals to not only track their inventory of contrast agents but to watch for patient safety issues, which are becoming critically important when contrast agents are used in an MR or CT suite,” said Douglas Stefanelli, vice president and general manager of diagnostic imaging for Bayer HealthCare Pharmaceuticals. “It also helps compliance with Joint Commission on Accreditation of Healthcare Organizations standards.”
When linked to an electronic medical record or radiology information system, the high-tech cabinet can flag information that may affect the use of contrast material, such as a patient’s glomerular filtration rate (an indicator of kidney disease) or potential allergic reactions, a cochlear implant, or a pacemaker. The password-protected cabinet further safeguards patients by restricting access to staff who are provided specially designed badges or PIN codes.
Previewed by Bayer at RSNA 2007, VistaTrak is scheduled to begin shipping in mid-2008. Bayer’s MR contrast agent Magnevist will be the first to carry a VistaTrak RFID tag.
The cabinet answers some of the challenges facing providers who are being tasked by federal and state regulators, as well as JCAHO, to reduce medication errors. It addresses them in an automated and cost-effective way, according to Scott Bertetti, Bayer’s associate director of business development for diagnostic imaging, using technnology developed by Mobile Aspects and customized by Bayer and Mobile Aspects specifically for the radiology department.
“We created a small cabinet, because real estate is at a premium in the radiology area,” Bertetti said. “We also changed the interface to fit workflow in the radiology department and to address Joint Commission concerns about the use of contrast.”
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.